Climb Bio, INC Form 4 insider transactions

Climb Bio, Inc. Director Thomas Stephen Basil was granted 40,000 stock options with an exercise price of $1.29 per share, vesting on the earlier of June 4, 2026, or the next annual meeting, as reported in a recent SEC Form 4 filing.

Director Douglas E. Williams reports acquisition of stock options in Climb Bio, Inc.

Kimberlee C Drapkin, a director of Climb Bio, Inc., acquired 80,000 stock options on March 28, 2025, according to a Form 4 filing.

Director Alexander Cumbo acquired stock options for 80,000 shares of Climb Bio, Inc. on March 28, 2025.

Director Thomas Stephen Basil reports the vesting and conversion of restricted stock units into Climb Bio common stock.

Emily Pimblett, SVP, Finance & CAO of Climb Bio, Inc., reports the conversion of restricted stock units and sale of common stock to cover tax obligations.

Aoife Brennan, President and CEO of Climb Bio, Inc., reports the acquisition of stock options exercisable for 1,150,000 shares of common stock.

Emily Pimblett, SVP, Finance and CAO of Climb Bio, Inc., reports the grant of stock options for 100,000 shares of common stock.

Brett Kaplan, Chief Operating Officer of Climb Bio, Inc., reports the acquisition of stock options.

Director Thomas Stephen Basil of Climb Bio, Inc. reports the conversion of restricted stock units into common stock on January 1, 2025.

Emily Pimblett, Chief Accounting Officer of Climb Bio, executed transactions involving common stock and restricted stock units, including a sale to cover tax obligations under a pre-arranged 10b5-1 trading plan.

Director Douglas E. Williams of Climb Bio, Inc. acquired stock options for 26,291 shares on November 11, 2024.

Emily Pimblett, Chief Accounting Officer of Eliem Therapeutics, recently executed transactions involving the company's common stock, including the conversion of restricted stock units and sales under a pre-arranged trading plan.

Chief Operating Officer of Eliem Therapeutics, Brett Kaplan, reports the acquisition of stock options and restricted stock units in the company.

Valerie Morisset, EVP, R&D and CSO of Eliem Therapeutics, Inc., recently sold a significant number of common stock shares over several transactions.

Valerie Morisset, EVP, R&D and CSO of Eliem Therapeutics, Inc., sold a portion of her holdings in two transactions on July 17 and 18, 2024.

Valerie Morisset, EVP, R&D and CSO of Eliem Therapeutics, Inc., sold 50,000 shares of common stock on July 16, 2024, at a price of $7.13 per share.

Valerie Morisset, EVP, R&D and CSO of Eliem Therapeutics, Inc., recently sold a significant number of common stock shares.

Valerie Morisset, EVP, R&D and CSO of Eliem Therapeutics, Inc., sold a total of 105,931 shares of common stock between July 9 and July 11, 2024.

Valerie Morisset, EVP, R&D and CSO of Eliem Therapeutics, sold 12,342 shares of common stock on July 5, 2024.

Valerie Morisset, EVP, R&D and CSO of Eliem Therapeutics, exercised stock options and sold shares on July 1st and 3rd, 2024.

RA Capital Management and affiliated entities report a substantial increase in their beneficial ownership of Eliem Therapeutics common stock following the acquisition of Tenet Medicines.

RA Capital Management, along with related entities and individuals, reported the acquisition of a stock option for 10,000 shares of Eliem Therapeutics.

Andrew David Levin, Executive Chairman of Eliem Therapeutics, acquired 10,000 stock options on June 26, 2024, at an exercise price of $7.89.

Director Adam Joseph Rosenberg acquired 10,000 stock options in Eliem Therapeutics, Inc. on June 26, 2024.

Director Judith Dunn acquired 10,000 stock options in Eliem Therapeutics, Inc. on June 26, 2024.

Director Simon Tate acquired 10,000 stock options in Eliem Therapeutics, Inc. on June 26, 2024.

Director Liam Ratcliffe acquired 10,000 stock options in Eliem Therapeutics, Inc. on June 26, 2024.

Eliem Therapeutics' CEO, Aoife Brennan, was granted stock options and restricted stock units on June 27, 2024, according to a Form 4 filing with the SEC.

Director Thomas Stephen Basil acquired shares and restricted stock units of Eliem Therapeutics in connection with the acquisition of Tenet Medicines.